Medical industry sponsorship of economic evaluations on new treatments are more likely to be found cost-effective than independent research across a range of diseases.

Lead author of the study, McMaster University professor Feng Xie, said that cost-effectiveness analyses (CEAs) are used to set prices and decide if new treatments or devices will be covered by insurance policies.

New drugs and technologies covered by insurance plans can be much more profitable than those not covered, which may lead to bias in CEAs funded by pharmaceutical or other medical industry firms.

His research team gleaned its data by analysing the results of more than 8,000 CEAs published between 1976 and March 2021. Nearly 30 per cent of these CEAs were sponsored by industry. His study was published by The BMJ on June 22.

“Our provincial and national health-care programs require cost effectiveness analysis for setting new drug or device prices, as well as in support of their coverage policies,” said Xie, a professor of the Department of Health Research Methods, Evidence, and Impact.

Xie said this is a critical issue for low or middle-income countries, who often cannot conduct their own CEAs and must instead rely on already published studies that may have industry bias.

“These countries may end up paying more than they are supposed to for new drugs or medical technology. Impartial CEAs are especially important for them,” said Xie.

“We must only use those CEAs conducted by independent bodies with full transparency to set the new drug price and support insurance coverage policy. This is important to ensure accessibility and sustainability of our health-care systems.”

In a related editorial in The BMJ, experts confirmed the importance of the study, calling for improved reporting of results, increased transparency, open-source cost-effectiveness models and more independent studies to reduce decision makers’ reliance on potentially biased CEAs.

Industry sponsorship of CEAs was defined by Xie as an analysis wholly or partially funded by drug, medical device or biotechnology companies.

Eligible CEAs were those that reported an incremental cost-effectiveness ratio using quality-adjusted life years or QALYs, a value for money measure of years lived in good health.

No external funding was received for this study.